319 related articles for article (PubMed ID: 16595936)
1. Effect of decrease in both postprandial blood glucose (PBG) and fasting blood glucose (FBG) levels in normal beagle dogs with nateglinide enteric coated granules and immediate release tablets.
Makino C; Ninomiya N; Sakai H; Orita H; Okano A; Yabuki A
Chem Pharm Bull (Tokyo); 2006 Apr; 54(4):409-14. PubMed ID: 16595936
[TBL] [Abstract][Full Text] [Related]
2. Nateglinide controlled release tablet containing compressionable enteric coated granules.
Makino C; Sakai H; Yabuki A
Chem Pharm Bull (Tokyo); 2010 Sep; 58(9):1136-41. PubMed ID: 20823590
[TBL] [Abstract][Full Text] [Related]
3. Design of nateglinide controlled release tablet containing erosion matrix tablet and multiple administration study in normal beagle dogs.
Makino C; Sakai H; Okano A; Yabuki A
Chem Pharm Bull (Tokyo); 2009 Sep; 57(9):907-13. PubMed ID: 19721250
[TBL] [Abstract][Full Text] [Related]
4. The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects.
Karara AH; Dunning BE; McLeod JF
J Clin Pharmacol; 1999 Feb; 39(2):172-9. PubMed ID: 11563410
[TBL] [Abstract][Full Text] [Related]
5. Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes.
Carroll MF; Gutierrez A; Castro M; Tsewang D; Schade DS
J Clin Endocrinol Metab; 2003 Nov; 88(11):5248-54. PubMed ID: 14602757
[TBL] [Abstract][Full Text] [Related]
6. Comparison of insulinotrophic actions of nateglinide with glibenclamide dissociated from absorption in conscious dogs.
Okamoto M; Ogihara N; Kawamura W; Ebihara S; Takiguchi K; Morita T; Uchida R; Yamaguchi J; Sakai T; Okuda Y; Hayashi Y; Arakawa Y; Kikuchi M
Metabolism; 2002 May; 51(5):575-81. PubMed ID: 11979388
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of efficacy between nateglinide and repaglinide in treating type 2 diabetes: a randomized controlled double-blind clinical trial].
Li JW; Tian HM; Yu HL; Zhang XX; Zhao GZ; Wang JN
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 36(2):267-70. PubMed ID: 15807285
[TBL] [Abstract][Full Text] [Related]
8. Nateglinide, a non-sulfonylurea rapid insulin secretagogue, increases pancreatic islet blood flow in rats.
Iwase M; Nakamura U; Uchizono Y; Nohara S; Sasaki N; Sonoki K; Iida M
Eur J Pharmacol; 2005 Aug; 518(2-3):243-50. PubMed ID: 16023099
[TBL] [Abstract][Full Text] [Related]
9. Nateglinide.
Dunn CJ; Faulds D
Drugs; 2000 Sep; 60(3):607-615; discussion 616-7. PubMed ID: 11030470
[TBL] [Abstract][Full Text] [Related]
10. [Acupoint injection of human placenta tissue fluid combined with oral administration of metformin hydrochloride enteric-coated tablets treating type 2 diabetes:a randomized controlled trial].
Wu J; He L
Zhongguo Zhen Jiu; 2016 Aug; 36(8):812-814. PubMed ID: 29231565
[TBL] [Abstract][Full Text] [Related]
11. Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients.
Voytovich MH; Haukereid C; Hjelmesaeth J; Hartmann A; Løvik A; Jenssen T
Clin Transplant; 2007; 21(2):246-51. PubMed ID: 17425753
[TBL] [Abstract][Full Text] [Related]
12. Effect of bioadhesive polymers, sodium salicylate, polyoxyethylene-9-lauryl ether, and method of preparation on the relative hypoglycemia produced by insulin enteric-coated capsules in diabetic beagle dogs.
Hosny EA; al-Shora HI; Elmazar MM
Drug Dev Ind Pharm; 2002 May; 28(5):563-70. PubMed ID: 12098845
[TBL] [Abstract][Full Text] [Related]
13. Enhanced dissolution and bioavailability of Nateglinide by microenvironmental pH-regulated ternary solid dispersion: in-vitro and in-vivo evaluation.
Wairkar S; Gaud R; Jadhav N
J Pharm Pharmacol; 2017 Sep; 69(9):1099-1109. PubMed ID: 28590055
[TBL] [Abstract][Full Text] [Related]
14. Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals.
Sato Y; Nishikawa M; Shinkai H; Sukegawa E
Diabetes Res Clin Pract; 1991 Apr; 12(1):53-9. PubMed ID: 1906797
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of mitiglinide versus nateglinide in newly diagnose patients with type 2 diabetes mellitus: a randomized double blind trial.
Li L; Yang M; Li Z; Yan X; Guo H; Pan H; Liu H; Liao Y; Yang G
Diabetes Obes Metab; 2012 Feb; 14(2):187-9. PubMed ID: 21895920
[TBL] [Abstract][Full Text] [Related]
16. Improvement of glucose tolerance by nateglinide occurs through enhancement of early phase insulin secretion.
Uto Y; Teno S; Iwamoto Y; Omori Y; Takizawa T
Metabolism; 2002 Jan; 51(1):20-4. PubMed ID: 11782867
[TBL] [Abstract][Full Text] [Related]
17. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
Kambayashi A; Blume H; Dressman J
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
[TBL] [Abstract][Full Text] [Related]
18. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.
Hanefeld M; Bouter KP; Dickinson S; Guitard C
Diabetes Care; 2000 Feb; 23(2):202-7. PubMed ID: 10868832
[TBL] [Abstract][Full Text] [Related]
19. Effect of glimepiride and nateglinide on serum insulin and glucose concentration in healthy cats.
Mori A; Lee P; Yamashita T; Nishimaki Y; Oda H; Saeki K; Miki Y; Mizutani H; Ishioka K; Honjo T; Arai T; Sako T
Vet Res Commun; 2009 Dec; 33(8):957-70. PubMed ID: 19728131
[TBL] [Abstract][Full Text] [Related]
20. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo.
Kalbag JB; Walter YH; Nedelman JR; McLeod JF
Diabetes Care; 2001 Jan; 24(1):73-7. PubMed ID: 11194245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
